Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

Andrew J Yee, Noopur S RajeDivision of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USAAbstract: Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast and prostate cancer. Denosumab is a monoclonal...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yee AJ, Raje NS
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
denosumab breast cancer prostate cancer bone loss
Geriatrics
RC952-954.6
Acceso en línea:https://doaj.org/article/e634a06fd60f46699b3fc6394d02c27f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares